See how DUPIXENT reduced severe exacerbations, improved lung function, reduced or eliminated OCS use, and has a demonstrated safety profile.

Adults and Pediatric Patients (12+ Years)


Reduced severe exacerbations
by up to 81%1,a

See Primary Endpoint Results

Lung Function

Rapid and sustained lung function improvement patients
can feel1-4,b

See Results

OCS Reduction/Elimination

Only FDA-approved biologic indicated for OCS-dependent asthma patients1

See Results

Quality of Life

Resulted in improved asthma control and quality of life1,c-e

See Results

Safety Data

Demonstrated safety data across asthma clinical trials1,5,6

See Safety Data

Study Designs

Studied up to 1 year in nearly 3000 asthma patients1,f

See Study Designs

aThrough Week 24 with DUPIXENT 300 mg Q2W + SOC (n=64) vs placebo + SOC (n=68) (0.20 vs 1.04; rate ratio: 0.19 [95% CI: 0.07, 0.56]) (baseline blood EOS ≥300 cells/µL, DRI12544, secondary endpoint).1

b470 mL improvement at Week 52 from baseline in pre-bronchodilator FEV1 with DUPIXENT 200 mg Q2W + SOC (n=264) vs 170 mL improvement with placebo + SOC (n=148) (baseline blood EOS ≥300 cells/µL, QUEST, secondary endpoint). ~72% of the total FEV1 improvement was seen after the first dose at Week 2.1,4

c75% of patients had improved ACQ-5 (asthma control) scores with DUPIXENT 200 mg Q2W + SOC vs 67% with placebo + SOC (OR: 1.46 [95% CI: 0.90, 2.35]) (baseline blood EOS ≥300 cells/µL, QUEST, secondary endpoint).1

d71% of patients had improved AQLQ(S) (quality of life) scores with DUPIXENT 200 mg Q2W + SOC vs 55% with placebo + SOC (OR: 2.02 [95% CI: 1.24, 3.32]) (baseline blood EOS ≥300 cells/µL, QUEST, secondary endpoint).1

eACQ-5 and AQLQ(S) were assessed as secondary endpoints but were ordered after the point at which the hierarchical break occurred. Results are descriptive.3

fThe asthma development program for patients aged 12 years and older included three randomized, double-blind, placebo-controlled, parallel-group, multicenter trials (DRI12544, QUEST, and VENTURE) of 24 to 52 weeks in treatment duration, which enrolled a total of 2888 subjects.1

Children (6-11 Years)


Demonstrated data across clinically meaningful endpoints1,3

See Results

Safety Data

Demonstrated safety profile in children with moderate-to-severe asthma1,3

See Results

Study Design

Studied up to 1 year in over 400 children with moderate-to-severe asthma1

See Results

ACQ-5, Asthma Control Questionnaire, 5-item version; AQLQ(S), Asthma Quality of Life Questionnaire, Standardized Version; EOS, eosinophils; FEV1, forced expiratory volume in 1 second; OCS, oral corticosteroid; OR, odds ratio; Q2W, once every 2 weeks; SOC, standard of care.